{"pmid":32316065,"title":"Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines.","text":["Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines.","Coronavirus disease 2019 (COVID-19) has caused a global pandemic in just a few months, causing millions infected. Nearly 20% of COVID-19 patients present severe coagulation abnormalities, which may occur in almost all of the severe and critical ill COVID-19 cases. Concomitant venous thromboembolism (VTE), a potential cause of unexplained deaths, has been frequently reported in COVID-19 cases, but its management is still challenging due to the complexity between antithrombotic therapy and coagulation disorders. Based on frontline practical experience and comprehensive literature review, here a panel of experts and physicians from China and Europe developed an evidence and opinion-based consensus on the prophylaxis and management of VTE associated with COVID-19. This statement aims for clinicians treating COVID-19 and provides practical recommendations in detailed situations, for example, how to choose thromboprophylactic measures for patients with diverse severity of disease and bleeding risk, or which kind of anticoagulant should be prescribed. With limited experience on COVID19-associated VTE, this expert consensus statement should be helpful for clinicians worldwide with specific suggestions.","Thromb Haemost","Zhai, Zhenguo","Li, Chenghong","Chen, Yaolong","Gerotziafas, Grigorios","Zhang, Zhenlu","Wan, Jun","Liu, Peng","Elalamy, Ismail","Wang, Chen","32316065"],"abstract":["Coronavirus disease 2019 (COVID-19) has caused a global pandemic in just a few months, causing millions infected. Nearly 20% of COVID-19 patients present severe coagulation abnormalities, which may occur in almost all of the severe and critical ill COVID-19 cases. Concomitant venous thromboembolism (VTE), a potential cause of unexplained deaths, has been frequently reported in COVID-19 cases, but its management is still challenging due to the complexity between antithrombotic therapy and coagulation disorders. Based on frontline practical experience and comprehensive literature review, here a panel of experts and physicians from China and Europe developed an evidence and opinion-based consensus on the prophylaxis and management of VTE associated with COVID-19. This statement aims for clinicians treating COVID-19 and provides practical recommendations in detailed situations, for example, how to choose thromboprophylactic measures for patients with diverse severity of disease and bleeding risk, or which kind of anticoagulant should be prescribed. With limited experience on COVID19-associated VTE, this expert consensus statement should be helpful for clinicians worldwide with specific suggestions."],"journal":"Thromb Haemost","authors":["Zhai, Zhenguo","Li, Chenghong","Chen, Yaolong","Gerotziafas, Grigorios","Zhang, Zhenlu","Wan, Jun","Liu, Peng","Elalamy, Ismail","Wang, Chen"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32316065","week":"202017|Apr 20 - Apr 26","doi":"10.1055/s-0040-1710019","source":"PubMed","topics":["Treatment"],"weight":1,"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664714520045551617,"score":8.518259,"similar":[{"pmid":32271988,"title":"Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia.","text":["Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia.","BACKGROUND: Since 3 months ago, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) broke out in Wuhan, China, and spread rapidly around the world. Severe novel coronavirus pneumonia (NCP) patients have abnormal blood coagulation function, but their venous thromboembolism(VTE) prevalence is still rarely mentioned. OBJECTIVES: To determine the incidence of VTE in patients with severe NCP. METHODS: In this study, 81 severe NCP patients in the Intensive Care Unit (ICU) of Union Hospital (Wuhan, China) were enrolled. The results of conventional coagulation parameters and lower limb vein ultrasonography of these patients were retrospectively collected and analyzed. RESULTS: The incidence of VTE in these patients was 25%(20/81), of which 8 patients with VTE events died. VTE group was different from non-VTE group in age, lymphocytes counts, activated partial thromboplastin time (APTT), D-dimer, etc. If 1.5 microg/mL was used as the D-dimer cut-off value to predicting VTE, the sensitivity was 85.0%, the specificity was 88.5% and the negative predictive value (NPV) was 94.7%. CONCLUSIONS: The incidence of VTE in patients with severe NCP is 25% (20/81), which may be related to poor prognosis. The significant increase of D-dimer in severe NCP patients is a good index for identifying high-risk groups of VTE.","J Thromb Haemost","Cui, Songping","Chen, Shuo","Li, Xiunan","Liu, Shi","Wang, Feng","32271988"],"abstract":["BACKGROUND: Since 3 months ago, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) broke out in Wuhan, China, and spread rapidly around the world. Severe novel coronavirus pneumonia (NCP) patients have abnormal blood coagulation function, but their venous thromboembolism(VTE) prevalence is still rarely mentioned. OBJECTIVES: To determine the incidence of VTE in patients with severe NCP. METHODS: In this study, 81 severe NCP patients in the Intensive Care Unit (ICU) of Union Hospital (Wuhan, China) were enrolled. The results of conventional coagulation parameters and lower limb vein ultrasonography of these patients were retrospectively collected and analyzed. RESULTS: The incidence of VTE in these patients was 25%(20/81), of which 8 patients with VTE events died. VTE group was different from non-VTE group in age, lymphocytes counts, activated partial thromboplastin time (APTT), D-dimer, etc. If 1.5 microg/mL was used as the D-dimer cut-off value to predicting VTE, the sensitivity was 85.0%, the specificity was 88.5% and the negative predictive value (NPV) was 94.7%. CONCLUSIONS: The incidence of VTE in patients with severe NCP is 25% (20/81), which may be related to poor prognosis. The significant increase of D-dimer in severe NCP patients is a good index for identifying high-risk groups of VTE."],"journal":"J Thromb Haemost","authors":["Cui, Songping","Chen, Shuo","Li, Xiunan","Liu, Shi","Wang, Feng"],"date":"2020-04-10T11:00:00Z","year":2020,"_id":"32271988","week":"202015|Apr 06 - Apr 12","doi":"10.1111/jth.14830","keywords":["d-dimer","blood coagulation","coagulation parameter","novel coronavirus pneumonia","venous thromboembolism"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"locations":["Wuhan","China","Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664637315678470144,"score":262.28128},{"pmid":32320517,"title":"High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients.","text":["High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients.","BACKGROUND: Coagulopathy is a common abnormality in patients with COVID-19. However, the exact incidence of venous thromboembolic event is unknown in anticoagulated severe COVID-19 patients. OBJECTIVES: Systematic assessment of VTE using complete duplex ultrasound (CDU) in anticoagulated COVID-19 patients. PATIENTS AND METHODS: We performed a retrospective study in 2 French intensive care units (ICU) were CDU is performed as a standard of care. A CDU from thigh to ankle at selected sites with Doppler waveforms and images was performed early during ICU stay in patients admitted with COVID-19. Anticoagulation dose was left to the discretion of the treating physician based on the individual risk of thrombosis. Patients were classified as treated with prophylactic anticoagulation or therapeutic anticoagulation. Pulmonary embolism was systematically searched in patients with persistent hypoxemia or secondary deterioration. RESULTS: From March 19(th) to April 11(th) of 2020, 26 consecutive patients with severe COVID-19 were screened for VTE. 8 patients (31%) were treated with prophylactic anticoagulation whereas 18 patients (69%) were treated with therapeutic anticoagulation. The overall rate of VTE in patients was 69%. The proportion of VTE was significantly higher in patients treated with prophylactic anticoagulation when compared to the other group (100% vs. 56%, respectively, p=0.03). Surprisingly, we found a high rate of thromboembolic events in COVID-19 patients treated with therapeutic anticoagulation, with 56% of VTE and 6 pulmonary embolisms. CONCLUSION: Our results suggest considering both systematic screening of VTE and early therapeutic anticoagulation in severe ICU COVID-19 patients.","J Thromb Haemost","Llitjos, Jean-Francois","Leclerc, Maxime","Chochois, Camille","Monsallier, Jean-Michel","Ramakers, Michel","Auvray, Malika","Merouani, Karim","32320517"],"abstract":["BACKGROUND: Coagulopathy is a common abnormality in patients with COVID-19. However, the exact incidence of venous thromboembolic event is unknown in anticoagulated severe COVID-19 patients. OBJECTIVES: Systematic assessment of VTE using complete duplex ultrasound (CDU) in anticoagulated COVID-19 patients. PATIENTS AND METHODS: We performed a retrospective study in 2 French intensive care units (ICU) were CDU is performed as a standard of care. A CDU from thigh to ankle at selected sites with Doppler waveforms and images was performed early during ICU stay in patients admitted with COVID-19. Anticoagulation dose was left to the discretion of the treating physician based on the individual risk of thrombosis. Patients were classified as treated with prophylactic anticoagulation or therapeutic anticoagulation. Pulmonary embolism was systematically searched in patients with persistent hypoxemia or secondary deterioration. RESULTS: From March 19(th) to April 11(th) of 2020, 26 consecutive patients with severe COVID-19 were screened for VTE. 8 patients (31%) were treated with prophylactic anticoagulation whereas 18 patients (69%) were treated with therapeutic anticoagulation. The overall rate of VTE in patients was 69%. The proportion of VTE was significantly higher in patients treated with prophylactic anticoagulation when compared to the other group (100% vs. 56%, respectively, p=0.03). Surprisingly, we found a high rate of thromboembolic events in COVID-19 patients treated with therapeutic anticoagulation, with 56% of VTE and 6 pulmonary embolisms. CONCLUSION: Our results suggest considering both systematic screening of VTE and early therapeutic anticoagulation in severe ICU COVID-19 patients."],"journal":"J Thromb Haemost","authors":["Llitjos, Jean-Francois","Leclerc, Maxime","Chochois, Camille","Monsallier, Jean-Michel","Ramakers, Michel","Auvray, Malika","Merouani, Karim"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32320517","week":"202017|Apr 20 - Apr 26","doi":"10.1111/jth.14869","keywords":["covid-19","sars-cov-2","anticoagulation","critical care","pulmonary embolism","venous thromboembolism"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["French"],"countries":["France"],"countries_codes":["FRA|France"],"_version_":1664815087858221056,"score":261.6398},{"pmid":32307014,"title":"Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19.","text":["Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19.","Since December 2019, a novel type of coronavirus disease (COVID-19) in Wuhan led to an outbreak throughout China and the rest of the world. To date, there have been more than 1,260,000 COVID-19 patients, with a mortality rate of approximately 5.44%. Studies have shown that coagulation dysfunction is a major cause of death in patients with severe COVID-19. Therefore, the People's Liberation Army Professional Committee of Critical Care Medicine and Chinese Society on Thrombosis and Hemostasis grouped experts from the frontline of the Wuhan epidemic to come together and develop an expert consensus on diagnosis and treatment of coagulation dysfunction associated with a severe COVID-19 infection. This consensus includes an overview of COVID-19-related coagulation dysfunction, tests for coagulation, anticoagulation therapy, replacement therapy, supportive therapy and prevention. The consensus produced 18 recommendations which are being used to guide clinical work.","Mil Med Res","Song, Jing-Chun","Wang, Gang","Zhang, Wei","Zhang, Yang","Li, Wei-Qin","Zhou, Zhou","32307014"],"abstract":["Since December 2019, a novel type of coronavirus disease (COVID-19) in Wuhan led to an outbreak throughout China and the rest of the world. To date, there have been more than 1,260,000 COVID-19 patients, with a mortality rate of approximately 5.44%. Studies have shown that coagulation dysfunction is a major cause of death in patients with severe COVID-19. Therefore, the People's Liberation Army Professional Committee of Critical Care Medicine and Chinese Society on Thrombosis and Hemostasis grouped experts from the frontline of the Wuhan epidemic to come together and develop an expert consensus on diagnosis and treatment of coagulation dysfunction associated with a severe COVID-19 infection. This consensus includes an overview of COVID-19-related coagulation dysfunction, tests for coagulation, anticoagulation therapy, replacement therapy, supportive therapy and prevention. The consensus produced 18 recommendations which are being used to guide clinical work."],"journal":"Mil Med Res","authors":["Song, Jing-Chun","Wang, Gang","Zhang, Wei","Zhang, Yang","Li, Wei-Qin","Zhou, Zhou"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32307014","week":"202017|Apr 20 - Apr 26","doi":"10.1186/s40779-020-00247-7","keywords":["covid-19","coagulation dysfunction","diagnosis","severe","treatment"],"source":"PubMed","topics":["Treatment","Diagnosis"],"weight":1,"locations":["Wuhan","China","Chinese","Wuhan","Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664632501399715842,"score":198.76157},{"pmid":32034659,"title":"Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts' consensus statement.","text":["Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts' consensus statement.","Since the outbreak of 2019 novel coronavirus infection (2019-nCoV) in Wuhan City, China, by January 30, 2020, a total of 9692 confirmed cases and 15,238 suspected cases have been reported around 31 provinces or cities in China. Among the confirmed cases, 1527 were severe cases, 171 had recovered and been discharged at home, and 213 died. And among these cases, a total of 28 children aged from 1 month to 17 years have been reported in China. For standardizing prevention and management of 2019-nCoV infections in children, we called up an experts' committee to formulate this experts' consensus statement. This statement is based on the Novel Coronavirus Infection Pneumonia Diagnosis and Treatment Standards (the fourth edition) (National Health Committee) and other previous diagnosis and treatment strategies for pediatric virus infections. The present consensus statement summarizes current strategies on diagnosis, treatment, and prevention of 2019-nCoV infection in children.","World J Pediatr","Shen, Kunling","Yang, Yonghong","Wang, Tianyou","Zhao, Dongchi","Jiang, Yi","Jin, Runming","Zheng, Yuejie","Xu, Baoping","Xie, Zhengde","Lin, Likai","Shang, Yunxiao","Lu, Xiaoxia","Shu, Sainan","Bai, Yan","Deng, Jikui","Lu, Min","Ye, Leping","Wang, Xuefeng","Wang, Yongyan","Gao, Liwei","32034659"],"abstract":["Since the outbreak of 2019 novel coronavirus infection (2019-nCoV) in Wuhan City, China, by January 30, 2020, a total of 9692 confirmed cases and 15,238 suspected cases have been reported around 31 provinces or cities in China. Among the confirmed cases, 1527 were severe cases, 171 had recovered and been discharged at home, and 213 died. And among these cases, a total of 28 children aged from 1 month to 17 years have been reported in China. For standardizing prevention and management of 2019-nCoV infections in children, we called up an experts' committee to formulate this experts' consensus statement. This statement is based on the Novel Coronavirus Infection Pneumonia Diagnosis and Treatment Standards (the fourth edition) (National Health Committee) and other previous diagnosis and treatment strategies for pediatric virus infections. The present consensus statement summarizes current strategies on diagnosis, treatment, and prevention of 2019-nCoV infection in children."],"journal":"World J Pediatr","authors":["Shen, Kunling","Yang, Yonghong","Wang, Tianyou","Zhao, Dongchi","Jiang, Yi","Jin, Runming","Zheng, Yuejie","Xu, Baoping","Xie, Zhengde","Lin, Likai","Shang, Yunxiao","Lu, Xiaoxia","Shu, Sainan","Bai, Yan","Deng, Jikui","Lu, Min","Ye, Leping","Wang, Xuefeng","Wang, Yongyan","Gao, Liwei"],"date":"2020-02-09T11:00:00Z","year":2020,"_id":"32034659","week":"20206|Feb 03 - Feb 09","doi":"10.1007/s12519-020-00343-7","source":"PubMed","topics":["Treatment","Diagnosis","Prevention"],"weight":1,"locations":["Wuhan","China","China","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664640875339186179,"score":185.11195},{"pmid":32111113,"title":"[The keypoints in treatment of the critical coronavirus disease 2019 patient].","text":["[The keypoints in treatment of the critical coronavirus disease 2019 patient].","The treatment of critically ill patients with coronavirus disease 2019(COVID-19) faces compelling challenges. In this issue, we'd like to share our first-line treatment experience in treating COVID-19. Hemodynamics need be closely monitored and different types of shock should be distinguished. Vasoconstrictor drugs should be used rationally and alerting of complications is of the same importance. The risk of venous thromboembolism (VTE) needs to be assessed, and effective prevention should be carried out for high-risk patients. It is necessary to consider the possibility of pulmonary thromboembolism (PTE) in patients with sudden onset of oxygenation deterioration, respiratory distress, reduced blood pressure. However, comprehensive analysis of disease state should be taken into the interpretation of abnormally elevated D-Dimer. Nutritional support is the basis of treatment. It's important to establish individual therapy regimens and to evaluate, monitor and adjust dynamically. Under the current epidemic situation, convalescent plasma can only be used empirically, indications need to be strictly screened, the blood transfusion process should be closely monitored and the curative effect should be dynamically evaluated.","Zhonghua Jie He He Hu Xi Za Zhi","Li, X Y","Du, B","Wang, Y S","Kang, H Y J","Wang, F","Sun, B","Qiu, H B","Tong, Z H","32111113"],"abstract":["The treatment of critically ill patients with coronavirus disease 2019(COVID-19) faces compelling challenges. In this issue, we'd like to share our first-line treatment experience in treating COVID-19. Hemodynamics need be closely monitored and different types of shock should be distinguished. Vasoconstrictor drugs should be used rationally and alerting of complications is of the same importance. The risk of venous thromboembolism (VTE) needs to be assessed, and effective prevention should be carried out for high-risk patients. It is necessary to consider the possibility of pulmonary thromboembolism (PTE) in patients with sudden onset of oxygenation deterioration, respiratory distress, reduced blood pressure. However, comprehensive analysis of disease state should be taken into the interpretation of abnormally elevated D-Dimer. Nutritional support is the basis of treatment. It's important to establish individual therapy regimens and to evaluate, monitor and adjust dynamically. Under the current epidemic situation, convalescent plasma can only be used empirically, indications need to be strictly screened, the blood transfusion process should be closely monitored and the curative effect should be dynamically evaluated."],"journal":"Zhonghua Jie He He Hu Xi Za Zhi","authors":["Li, X Y","Du, B","Wang, Y S","Kang, H Y J","Wang, F","Sun, B","Qiu, H B","Tong, Z H"],"date":"2020-03-01T11:00:00Z","year":2020,"_id":"32111113","week":"20209|Feb 24 - Mar 01","doi":"10.3760/cma.j.cn112147-20200224-00159","keywords":["convalescent plasma","coronavirus disease 2019, covid-19","nutritional support","vasoconstrictor drugs","venous thromboembolism"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664640875087527936,"score":184.2254}]}